Amgen Reports Phase 3 Results for Xgeva in Giant Cell Tumor of Bone

Amgen today announced Phase 3 trial results for Xgeva (denosumab) in patients with giant cell tumor of bone. The trial demonstrated significant reductions in tumor progression and improvements in surgical outcomes compared to historical controls. These results support the use of Xgeva in giant cell tumor of bone.